# The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial

> **NCT03158935** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 8 (actual)

## Conditions studied

- Advanced Ovarian Cancer
- Malignant Melanoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **PROCEDURE:** Pembrolizumab
- **BIOLOGICAL:** Tumor-Infiltrating Lymphocytes (TILs)
- **BIOLOGICAL:** Interleukin-2 (IL-2)

## Key facts

- **NCT ID:** NCT03158935
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-07
- **Primary completion:** 2020-08-04
- **Final completion:** 2020-08-04
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158935, "The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03158935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*